Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial

By sjmartinez • November 4, 2022

Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, Denton CP, Wuyts WA, Miede C, Alves M, Sambevski S, Allanore Y. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408. doi: 10.1093/rheumatology/keac091. PMID: 35150246.

Tags: Connective tissue diseases, Nintedanib, Publications, Rheumatology, systemic Scleroderma, Vital capacity

Related Posts

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu[...]

Reperfusion Strategies for Acute Pulmonary Embolism: Design and Rationale of RECONNECT-PE – a Living Systematic Review and Meta-analysis

Farmakis IT, Binder H, Chopard R, Christodoulou KC, Evrenoglou T, Fengler K, Giri J, Hobohm L, Jaber WA, Klok FA, Kocka V, Kroupa J, Kucher[...]

Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis

Shimizu T, Zheng S, Maeda S, Link J, Deranteriassian A, Premji A, King J, Girgis M, Hines OJ, Wainberg Z, Raldow A, He J, Burns[...]